04:46 AM EDT, 06/24/2024 (MT Newswires) -- argenx (ARGX) said late Friday the US Food and Drug Administration has approved Vyvgart Hytrulo for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy, a neuromuscular disorder that causes a range of disabling mobility and sensory issues.

The approval is based on a clinical trial in which 69% of patients treated with Vyvgart Hytrulo showed evidence of clinical improvement, including in mobility, function and strength, the company said.

Vyvgart Hytrulo was approved as a once weekly 30-to-90 second subcutaneous injection, argenx said.

The company's share price was up almost 8% in premarket activity Monday.

Price: 410.00, Change: +31.32, Percent Change: +7.94